Table 1.
Summary of approved BTK inhibitors.
| BTK Inhibitor | Year of FDA Approval | Generation | BTK Inhibition | Indication |
|---|---|---|---|---|
| Ibrutinib (Imbruvica) | 2013 | First | Irreversible | CLL/SLL, GVHD, MCL, MZL, WM |
| Acalabrutinib (Calquence) | 2017 | Second | Irreversible | CLL/SLL, MCL |
| Zanubrutinib (Brukinsa) | 2019 | Second | Irreversible | CLL/SLL, MCL, MZL, WM |
| Pirtobrutinib (Jaypirca) | 2023 | Third | Reversible | CLL/SLL, MCL |
Abbreviations: chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma (SLL), graft-versus-host disease (GVHD); mantle cell lymphoma (MCL); marginal zone lymphoma (MZL); Waldenstrom macroglobulinemia (WM).